Skip to main navigation Skip to search Skip to main content

4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress

  • Marissa L Calbert
  • , Gurushankar Chandramouly
  • , Clare M Adams
  • , Magali Saez-Ayala
  • , Tatiana Kent
  • , Mrityunjay Tyagi
  • , V S S Abhinav Ayyadevara
  • , Yifan Wang
  • , John J. Krais
  • , John Gordon
  • , Jessica Atkins
  • , Monika M Toma
  • , Stéphane Betzi
  • , Andrew S Boghossian
  • , Matthew G Rees
  • , Melissa M Ronan
  • , Jennifer A Roth
  • , Aaron R Goldman
  • , Nicole Gorman
  • , Ramkrishna Mitra
  • Wayne E Childers, Xavier Graña, Tomasz Skorski, Neil Johnson, Christian Hurtz, Xavier Morelli, Christine M Eischen, Richard T Pomerantz
  • Thomas Jefferson University
  • Centre de Recherche en Cancérologie de Marseille
  • Lewis Katz School of Medicine, Temple University
  • Fox Chase Cancer Center
  • Temple University School of Pharmacy Drug
  • Temple University School of Medicine
  • Temple University
  • Broad Institute
  • The Wistar Institute
  • Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Loma Linda University Health

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Anticancer nucleosides are effective against solid tumors and hematologic malignancies, but typically are prone to nucleoside metabolism resistance mechanisms. Using a nucleoside-specific multiplexed high-throughput screening approach, we discovered 4'-ethynyl-2'-deoxycytidine (EdC) as a third-generation anticancer nucleoside prodrug with preferential activity against diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). EdC requires deoxycytidine kinase (DCK) phosphorylation for its activity and induces replication fork arrest and accumulation of cells in S-phase, indicating it acts as a chain terminator. A 2.1Å cocrystal structure of DCK bound to EdC and UDP reveals how the rigid 4'-alkyne of EdC fits within the active site of DCK. Remarkably, EdC was resistant to cytidine deamination and SAMHD1 metabolism mechanisms and exhibited higher potency against ALL compared with FDA-approved nelarabine. Finally, EdC was highly effective against DLBCL tumors and B-ALL in vivo. These data characterize EdC as a preclinical nucleoside prodrug candidate for DLBCL and ALL.

Original languageEnglish
Pages (from-to)683-699
Number of pages17
JournalMolecular Cancer Therapeutics
Volume23
Issue number5
Early online dateNov 8 2023
DOIs
StatePublished - May 2 2024

Keywords

  • Animals
  • Cell Line, Tumor
  • Deoxycytidine Kinase/metabolism
  • Deoxycytidine/analogs & derivatives
  • Humans
  • Leukemia/drug therapy
  • Lymphoma/drug therapy
  • Mice
  • Xenograft Model Antitumor Assays

Fingerprint

Dive into the research topics of '4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress'. Together they form a unique fingerprint.

Cite this